MENU
+Compare
BLTE
Stock ticker: NASDAQ
AS OF
Aug 11, 01:02 PM (EDT)
Price
$70.98
Change
+$1.10 (+1.57%)
Capitalization
2.27B

BLTE Belite Bio Forecast, Technical & Fundamental Analysis

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout... Show more

BLTE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BLTE with price predictions
Aug 08, 2025

BLTE's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for BLTE moved out of overbought territory on August 05, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 instances where the indicator moved out of the overbought zone. In of the 19 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for BLTE moved below the 200-day moving average on July 10, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLTE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BLTE broke above its upper Bollinger Band on August 04, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 29, 2025. You may want to consider a long position or call options on BLTE as a result. In of 66 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BLTE just turned positive on July 23, 2025. Looking at past instances where BLTE's MACD turned positive, the stock continued to rise in of 27 cases over the following month. The odds of a continued upward trend are .

BLTE moved above its 50-day moving average on July 25, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BLTE crossed bullishly above the 50-day moving average on July 30, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BLTE advanced for three days, in of 194 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 157 cases where BLTE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BLTE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.388) is normal, around the industry mean (18.662). P/E Ratio (0.000) is within average values for comparable stocks, (54.033). BLTE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.909). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (286.048).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLTE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
BLTE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

BLTE is expected to report earnings to rise 43.70% to -38 cents per share on August 11

Belite Bio BLTE Stock Earnings Reports
Q2'25
Est.
$-0.39
Q1'25
Beat
by $0.10
Q4'24
Est.
$-0.32
Q3'24
Beat
by $0.01
Q2'24
Missed
by $0.05
The last earnings report on May 14 showed earnings per share of -27 cents, beating the estimate of -37 cents. With 8.68K shares outstanding, the current market capitalization sits at 2.27B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
12750 High Bluff Drive
Phone
+1 858 246-6240
Employees
20
Web
https://www.belitebio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDMLX11.210.08
+0.72%
Fidelity Series Intrinsic Opps
JGASX44.550.24
+0.54%
JPMorgan Growth Advantage I
CDOFX46.670.12
+0.26%
Crawford Small Cap Dividend
GHTRX15.400.03
+0.20%
Goldman Sachs International T/M Eq R6
GLNBX21.66-0.02
-0.09%
MFS Global New Discovery B

BLTE and Stocks

Correlation & Price change

A.I.dvisor tells us that BLTE and ACOG have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BLTE and ACOG's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BLTE
1D Price
Change %
BLTE100%
-0.30%
ACOG - BLTE
27%
Poorly correlated
+8.43%
FGHQF - BLTE
25%
Poorly correlated
N/A
URGN - BLTE
23%
Poorly correlated
-4.55%
HRMY - BLTE
23%
Poorly correlated
N/A
LENZ - BLTE
23%
Poorly correlated
+7.97%
More